Last edition
News about "Amber U Luong"
Phase 3 results show Dupixent significantly improved nasal symptoms and sinus health in patients aged six and above with allergic fungal rhinosinusitis, supporting its FDA priority review.
Amber U Luong | 10/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members